...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex
【24h】

Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex

机译:通过血脑屏障的载体介导的125 I标记的β淀粉样肽A beta 1-40的传递,并与A beta 1-40 /载体复合物的阿尔茨海默氏病淀粉样蛋白结合

获取原文
获取原文并翻译 | 示例
           

摘要

The brain amyloid of Alzheimer disease (AD) may potentially be imaged in patients with AD by using neuroimaging technology and a radiolabeled form of the 40-residue beta-amyloid peptide A beta 1-40 that is enabled to undergo transport through the brain capillary endothelial wall, which makes up the blood-brain barrier (BBB) in vivo. Transport of 125I-labeled A beta 1-40 (125I-A beta 1-40) through the BBB was found to be negligible by experiments with both an intravenous injection technique and an internal carotid artery perfusion method in anesthetized rats. In addition, 125I-A beta 1-40 was rapidly metabolized after either intravenous injection or internal carotid artery perfusion. BBB transport was increased and peripheral metabolism was decreased by conjugation of monobiotinylated 125I-A beta 1-40 to a vector-mediated drug delivery system, which consisted of a conjugate of streptavidin (SA) and the OX26 monoclonal antibody to the rat transferrin receptor, which undergoes receptor-mediated transcytosis through the BBB. The brain uptake, expressed as percent of injected dose delivered per gram of brain, of the 125I,bio-A beta 1-40/SA-OX26 conjugate was 0.15 +/- 0.01, a level that is 2-fold greater than the brain uptake of morphine. The binding of the 125I,bio-A beta 1-40/SA-OX26 conjugate to the amyloid of AD brain was demonstrated by both film and emulsion autoradiography performed on frozen sections of AD brain. Binding of the 125I,bio-A beta 1-40/SA-OX26 conjugate to the amyloid of AD brain was completely inhibited by high concentrations of unlabeled A beta 1-40. In conclusion, these studies show that BBB transport and access to amyloid within brain may be achieved by conjugation of A beta 1-40 to a vector-mediated BBB drug delivery system.
机译:阿尔茨海默氏病(AD)的大脑淀粉样蛋白可能会通过使用神经影像技术和40残基β淀粉样肽A beta 1-40的放射性标记形式在AD患者中成像,从而能够通过脑毛细血管内皮运输壁,构成了体内的血脑屏障(BBB)。通过静脉注射技术和颈内动脉灌注方法对麻醉大鼠的实验发现,125I标记的A beta 1-40(125I-A beta 1-40)通过BBB的运输可以忽略不计。此外,静脉注射或颈内动脉灌注后125I-A beta 1-40迅速代谢。通过单生物素化的125I-A beta 1-40与载体介导的药物传递系统的偶联,可增加BBB的运输,降低外周代谢,该系统由链霉亲和素(SA)和针对大鼠转铁蛋白受体的OX26单克隆抗体的缀合物组成,它通过BBB进行受体介导的胞吞作用。 125 I,bio-A beta 1-40 / SA-OX26共轭物的大脑摄取量以每克大脑中注射剂量的百分比表示,为0.15 +/- 0.01,比大脑高2倍吸收吗啡。 125I,bio-Aβ1-40 / SA-OX26缀合物与AD脑淀粉样蛋白的结合通过对AD脑冷冻切片进行的胶片和乳胶放射自显影来证明。高浓度的未标记A beta 1-40完全抑制了125I,bio-A beta 1-40 / SA-OX26缀合物与AD脑淀粉样蛋白的结合。总之,这些研究表明,通过将A beta 1-40与载体介导的BBB药物递送系统结合,可以实现BBB在脑内的运输和淀粉样蛋白的进入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号